Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. The company develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin. It also develops APL-9 for intravenous administration in systemic indications, which is in single ascending dose Phase I clinical trial. The company has a development agreement with Enable Injections, Inc. to develop wearable devices for subcutaneous delivery of high-volume therapeutics. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [02/12/2019 07:40 PST] APLS Expected to Trade Down Short Term
• [02/11/2019 10:29 PST] Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), Up By 100.00% ($13.20) From $13.200 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [02/04/2019 07:43 PST] APLS Expected to Trade Down Short Term
• [01/28/2019 07:38 PST] APLS Expected to Trade Up After Bullish Patterns Develop
• [01/25/2019 07:31 PST] APLS Expected to Trade Down After Bearish Patterns Develop
• [01/23/2019 07:39 PST] APLS Expected to Trade Down Short Term
• [01/16/2019 10:29 PST] APLS SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.